Periodic Reporting for period 2 - NEUROCOV (The pandemic within: tackling brain vulnerability in COVID19 at high resolution: NEUROCOV)
Berichtszeitraum: 2024-03-01 bis 2025-08-31
This project focuses on the long-term neurological and neuropsychiatric complications of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emerging pandemic within the COVID-19 pandemic with a predicted major impact on individual and societal welfare. This project wants to understand the long-term effects COVID-19 can have on our brain and mental health. We have seen more people experiencing ongoing issues like memory problems and mood changes even after they have recovered from the virus. This is especially noticeable with newer variants like omicron and delta.
Numerous reports suggest that inflammation in both the central nervous system and throughout the body might be a big part of why some people develop these lasting problems. But there's still a lot we don't know about how exactly the virus affects our brains and why some people are more affected than others. So, the NEUROCOV project aims to dig deep into these questions. Here is what we are focusing on:
- Understanding the different ways COVID-19 can impact our thinking and memory in the long run.
- Figuring out the specific biological mechanisms behind these effects.
- Identifying which types of brain cells are most vulnerable to the virus and why.
- Creating experimental models that mimic the genetic diversity of people in Europe to help us study these effects better.
- Using artificial intelligence to predict who might be at risk for these long-term brain issues.
- Searching for potential treatments using computer simulations and testing them on laboratory-grown brain organoids from patients.
- Making sure we are listening to and addressing the social challenges faced by people dealing with these long-term effects.
Ultimately, our goal is to better understand and treat the long-term impact COVID-19 can have on our brains and mental health.
Numerous reports suggest that inflammation in both the central nervous system and throughout the body might be a big part of why some people develop these lasting problems. But there's still a lot we don't know about how exactly the virus affects our brains and why some people are more affected than others. So, the NEUROCOV project aims to dig deep into these questions. Here is what we are focusing on:
- Understanding the different ways COVID-19 can impact our thinking and memory in the long run.
- Figuring out the specific biological mechanisms behind these effects.
- Identifying which types of brain cells are most vulnerable to the virus and why.
- Creating experimental models that mimic the genetic diversity of people in Europe to help us study these effects better.
- Using artificial intelligence to predict who might be at risk for these long-term brain issues.
- Searching for potential treatments using computer simulations and testing them on laboratory-grown brain organoids from patients.
- Making sure we are listening to and addressing the social challenges faced by people dealing with these long-term effects.
Ultimately, our goal is to better understand and treat the long-term impact COVID-19 can have on our brains and mental health.
During the project timeline from March 1st, 2024, to August 31th, 2025, our team has engaged in making progress toward the project goals.
- The consortium has made significant progress in understanding post-COVID-19 neurological sequelae through the steady enrolment of participants in two independent Italian and German cohorts. Key achievements include the recruitment of over 300 individuals, with a focus on diverse symptomatology, particularly fatigue and cognitive impairments. Biological samples for high-dimensional analyses have been successfully collected, including blood and cerebrospinal fluid, to explore potential neurological risks and genetic vulnerabilities. Epidemiological studies are also ongoing and so far highlighted a threefold increased risk of severe neurological complications following COVID-19, with ongoing analyses set to enhance our understanding of these conditions. Collaborative efforts to harmonize methodologies between cohorts are also underway, ensuring robust data integration for future research.
- The study has achieved significant milestones in understanding post‑COVID‑19 with neurological sequelae through comprehensive multi-omics profiling and patient-specific disease trajectory identification. We generated single-cell multiOMIC profiles for almost 300 individuals, revealing potential blood biomarkers linked to post-COVID syndrome. High-dimensional flow cytometry and proteomic analyses were conducted, providing insights into neuroinflammatory mediators. Our teams have prioritized patients for induced pluripotent stem cells (iPSCs) reprogramming, useful for the generation of in vitro brain organoid models of the disease. Research on host viral restriction factors is underway, with genome-wide screens prepared using human pluripotent stem cell-derived neurons. Overall, the project is paving the way for deeper insights into the cellular and molecular mechanisms of NeuroCOVID.
- The project has made significant contributions in defining patient profiles through single-cell analyses, including transcriptional disease fingerprints for immune cells in patients with post‑COVID‑19 associated neurological symptoms. We also focused on developing causal artificial intelligence (AI) methods for mapping regulatory networks, enabling predictive modeling of disease states. The project aims to integrate diverse data sources for comprehensive analysis and validation in the coming months.
- During this reporting period, significant progress has been made concerning societal and ethical aspects of neurological post‑COVID‑19. We completed a meta-review of literature and social media on NEUROCOV advocacy by April 2024, gathering qualitative data from healthcare professionals, researchers, and patient organizations. We also investigated the challenges related to data sharing within COVID-19 health data infrastructures in Europe, with findings leading to three publications addressing the European Health Data Space. Ongoing analyses of data valorisation practices and AI model access challenges are also in progress. Overall, the project is successfully addressing the ethical, legal, and social implications of NEUROCOV research.
- The consortium has made significant progress in understanding post-COVID-19 neurological sequelae through the steady enrolment of participants in two independent Italian and German cohorts. Key achievements include the recruitment of over 300 individuals, with a focus on diverse symptomatology, particularly fatigue and cognitive impairments. Biological samples for high-dimensional analyses have been successfully collected, including blood and cerebrospinal fluid, to explore potential neurological risks and genetic vulnerabilities. Epidemiological studies are also ongoing and so far highlighted a threefold increased risk of severe neurological complications following COVID-19, with ongoing analyses set to enhance our understanding of these conditions. Collaborative efforts to harmonize methodologies between cohorts are also underway, ensuring robust data integration for future research.
- The study has achieved significant milestones in understanding post‑COVID‑19 with neurological sequelae through comprehensive multi-omics profiling and patient-specific disease trajectory identification. We generated single-cell multiOMIC profiles for almost 300 individuals, revealing potential blood biomarkers linked to post-COVID syndrome. High-dimensional flow cytometry and proteomic analyses were conducted, providing insights into neuroinflammatory mediators. Our teams have prioritized patients for induced pluripotent stem cells (iPSCs) reprogramming, useful for the generation of in vitro brain organoid models of the disease. Research on host viral restriction factors is underway, with genome-wide screens prepared using human pluripotent stem cell-derived neurons. Overall, the project is paving the way for deeper insights into the cellular and molecular mechanisms of NeuroCOVID.
- The project has made significant contributions in defining patient profiles through single-cell analyses, including transcriptional disease fingerprints for immune cells in patients with post‑COVID‑19 associated neurological symptoms. We also focused on developing causal artificial intelligence (AI) methods for mapping regulatory networks, enabling predictive modeling of disease states. The project aims to integrate diverse data sources for comprehensive analysis and validation in the coming months.
- During this reporting period, significant progress has been made concerning societal and ethical aspects of neurological post‑COVID‑19. We completed a meta-review of literature and social media on NEUROCOV advocacy by April 2024, gathering qualitative data from healthcare professionals, researchers, and patient organizations. We also investigated the challenges related to data sharing within COVID-19 health data infrastructures in Europe, with findings leading to three publications addressing the European Health Data Space. Ongoing analyses of data valorisation practices and AI model access challenges are also in progress. Overall, the project is successfully addressing the ethical, legal, and social implications of NEUROCOV research.
Our results push the frontiers of post-COVID-19 research beyond the current state of the art by delivering an unprecedented, integrative view that combines large‑scale clinical phenotyping, high‑dimensional multi‑omics, cutting‑edge stem‑cell modelling, and causal AI analytics while simultaneously addressing the ethical, legal and societal dimensions of data use. Within the 18‑month project window (Mar 2024 – Aug 2025) we have enrolled >300 participants across harmonised Italian and German cohorts, capturing a broad spectrum of fatigue, cognitive deficits and other neuro‑behavioural symptoms, and have collected paired blood and cerebrospinal‑fluid samples for single‑cell multi‑omics profiling of nearly 300 individuals. This effort will ultimately uncover novel blood‑based biomarkers and neuroinflammatory mediators as well as enable the generation of patient‑specific iPSC‑derived brain organoids for functional validation. By combining different approaches, we are unveiling previously unknown host-viral restriction factors and delineated regulatory networks that drive disease trajectories—insights that are now being encoded into causal AI models capable of predicting individual disease courses from multi‑modal data. In parallel, our meta‑review of literature and social‑media discourse, together with systematic analyses of data‑sharing barriers in the European Health Data Space is setting new standards for responsible data valorisation and AI accessibility in pandemic‑related research. Collectively, these breakthroughs—spanning biomarker discovery, mechanistic neurobiology, predictive modelling, and governance—will constitute a truly next‑generation knowledge base that opens concrete pathways toward precision diagnostics, targeted therapeutics, and ethically sound implementation for patients experiecing post‑COVID‑19 neurological sequelae.